Median overall survival in melanoma with nivolumab plus ipilimumab presented at ESMO24 – NEJM

NEJM posted the following on X:

“Presented at ESMO24:

Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone.

Full CheckMate 067 trial results.”

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

Authors: Jedd D. Wolchok, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., Piotr Rutkowski, M.D., Ph.D., C. Lance Cowey, M.D., M.P.H., Dirk Schadendorf, M.D., John Wagstaff, M.D., Paola Queirolo, M.D., Reinhard Dummer, M.D., Marcus O. Butler, M.D., Andrew G. Hill, M.D., Michael A. Postow, M.D., Caroline Gaudy-Marqueste, M.D., Ph.D., Theresa Medina, M.D., Christopher D. Lao, M.D., John Walker, M.D., Iván Márquez-Rodas, M.D., Ph.D., John B.A.G. Haanen, M.D., Ph.D., Massimo Guidoboni, M.D., Michele Maio, M.D., Ph.D., Patrick Schöffski, M.D., Ph.D., Matteo S. Carlino, M.D., Shahneen Sandhu, M.D., Céleste Lebbé, M.D., Ph.D., Paolo A. Ascierto, M.D., Georgina V. Long, M.D., Ph.D., Corey Ritchings, Pharm.D., Ayman Nassar, M.B., B.S., Margarita Askelson, M.S., Melanie Pe Benito, M.Sc., Wenjia Wang, Ph.D., F. Stephen Hodi, M.D., and James Larkin, F.R.C.P., Ph.D.,

Source: NEJM/X